Loss or Gain of Function Mutations in ACOX1 Cause Axonal Loss Via Different Mechanisms.
Chung, H; Wangler, MF; Marcogliese, P; Jo, J; Ravenscoft, T; Duraine, L; Sadeghzadeh, S; Li-Kroeger, D; Schmidt, RE; Pestronk, A; et al.
2019.
Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups.
Rothwell, S; Chinoy, H; Lamb, JA; Miller, FW; Rider, LG; Wedderburn, LR; McHugh, NJ; Mammen, AL; Betteridge, ZE; Tansley, SL; et al.
Annals of the Rheumatic Diseases.
2019;
78:996-1002.
American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic Lupus Erythematosus.
Brunner, HI; Holland, MJ; Beresford, MW; Ardoin, SP; Appenzeller, S; Silva, CA; Flores, F; Aydin, PO A; Wenderfer, SE; Levy, DM; et al.
Arthritis Care and Research.
2019;
71:579-590.
Validation of the Cutaneous Lupus Erythematosus Disease Area and Severity Index and pSkindex27 for use in childhood-onset systemic lupus erythematosus.
Ale'Ed, A; Aydin, PO A; Al Mutairi, N; Alsaleem, A; Sonmez, HE; Henrickson, M; Huggins, JL; Ozen, S; Al-Mayouf, SM; Brunner, HI.
Lupus Science and Medicine.
2018;
5:e000275-e000275.
A plausibly causal functional lupus-associated risk variant in the STAT1-STAT4 locus.
Patel, ZH; Lu, X; Miller, D; Forney, CR; Lee, J; Lynch, A; Schroeder, C; Parks, L; Magnusen, AF; Chen, X; et al.
Human Molecular Genetics.
2018;
27:2392-2404.
Association of Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies With DRB1*07:01 and Severe Myositis in Juvenile Myositis Patients.
Kishi, T; Rider, LG; Pak, K; Barillas-Arias, L; Henrickson, M; McCarthy, PL; Shaham, B; Weiss, PF; Horkayne-Szakaly, I; Targoff, IN; et al.
Arthritis Care and Research.
2017;
69:1088-1094.
Tocilizumab reverses cerebral vasculopathy in a patient with homozygous SAMHD1 mutation.
Henrickson, M; Wang, H.
Clinical Rheumatology.
2017;
36:1445-1451.
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.
Rider, LG; Bayat, N; Feldman, BM; Cimaz, R; Cuttica, RJ; de Oliveira, SK; Lindsley, CB; Pilkington, CA; Reed, AM; Rouster-Stevens, K; et al.
Arthritis and Rheumatology.
2017;
69:911-923.
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.
Rider, LG; Aggarwal, R; Pistorio, A; Bayat, N; Erman, B; Feldman, BM; Huber, AM; Cimaz, R; Cuttica, RJ; de Oliveira, SK; et al.
Annals of the Rheumatic Diseases.
2017;
76:782-791.
2010 American College of Rheumatology Adult Fibromyalgia Criteria for Use in an Adolescent Female Population with Juvenile Fibromyalgia.
Ting, TV; Barnett, K; Lynch-Jordan, A; Whitacre, C; Henrickson, M; Kashikar-Zuck, S.
The Journal of Pediatrics.
2016;
169:181-7.e1.